Skip to content

The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy

The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06607887
Enrollment
300
Registered
2024-09-23
Start date
2024-08-30
Completion date
2024-12-30
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection Wound, Antibiotic Resistant Infection

Keywords

antibiotic, prophylaxis, cholecystectomy, postoperative

Brief summary

Comparison between postoperative parenteral prophylactic antibiotics, and oral antibiotics regarding the incidence of post laparoscopic cholecystectomy infection.

Interventions

DRUGIV antibiotic

Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.

Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.

Sponsors

Minia University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (aged above 18 years) undergoing laparoscopic cholecystectomy.

Exclusion criteria

* patients with comorbidities (Diabetes, malignancies, Immunosuppressed). Lost of follow-up. Patients received antibiotics within 72 hr before admission. Complicated cases involved, gangrenous and perforated cholecystitis and abscess.

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infection4 weeksDSSI = deep surgical site infection; SSSI = superficial surgical site infection.

Secondary

MeasureTime frame
Fever4 weeks
Length of the hospital stay4 weeks
Hematoma and Seroma formation4 weeks

Countries

Egypt

Contacts

Primary ContactAsmaa A Elsayed
asmaa.abdelfattah@pharm.sohag.edu.eg01095727201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026